Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01915602
Registration number
NCT01915602
Ethics application status
Date submitted
24/07/2013
Date registered
5/08/2013
Date last updated
8/04/2021
Titles & IDs
Public title
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Query!
Scientific title
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Query!
Secondary ID [1]
0
0
2013-000241-39
Query!
Secondary ID [2]
0
0
16728
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Hepatocellular
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Liver
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Refametinib (BAY86-9766)
Treatment: Drugs - Sorafenib (BAY43-9006)
Experimental: Refametinib and Sorafenib (Nexavar) - In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of =3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
Treatment: Drugs: Refametinib (BAY86-9766)
Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
Treatment: Drugs: Sorafenib (BAY43-9006)
Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Approximately 36 months
Query!
Secondary outcome [1]
0
0
Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Approximately 36 months
Query!
Secondary outcome [2]
0
0
Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Approximately 36 months
Query!
Secondary outcome [3]
0
0
Disease control (central and investigator's assessment)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Approximately 36 months
Query!
Secondary outcome [4]
0
0
Overall survival
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Approximately 36 months
Query!
Secondary outcome [5]
0
0
Time to radiographic tumor progression (central and investigator's assessment)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Approximately 36 months
Query!
Secondary outcome [6]
0
0
Duration of response (central and investigator's assessment)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Approximately 36 months
Query!
Secondary outcome [7]
0
0
Time to objective response (central and investigator's assessment).
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Approximately 36 months
Query!
Secondary outcome [8]
0
0
Change in tumor size (central and investigator's assessment)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Approximately 36 months
Query!
Secondary outcome [9]
0
0
Best overall response (central and investigator's assessment)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Approximately 36 months
Query!
Secondary outcome [10]
0
0
Progression-free survival (central and investigator's assessment)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Approximately 36 months
Query!
Secondary outcome [11]
0
0
Number of participants with adverse events as a measure of safety and tolerability
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Approximately 36 months
Query!
Eligibility
Key inclusion criteria
Eligibility criteria for RAS mutation testing
- Unresectable or metastatic HCC, confirmed either by histology or clinically according
to the American Association for the Study of Liver Disease (AASLD) criteria for
cirrhotic patients. For non-cirrhotic patients, histological confirmation is
mandatory.
- Male or female =18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
- Life expectancy of at least 12 weeks.
- No prior use of targeted agents, experimental therapy or systemic anti-cancer
treatment.
- No previous treatment with sorafenib or refametinib. Criteria for study treatment
eligibility
- Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or
Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions,
amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma
test.
- Patients must have at least one uni-dimensional measurable lesion by Computed
tomography (CT) or Magnetic resonance (MR) according to Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1 and Modified Response Evaluation Criteria in Solid Tumors
(mRECIST) which is either naïve (not previously treated by local therapy such as
surgery, radiation therapy, hepatic arterial therapy, chemoembolization,
radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously
treated and has progressed until baseline (both measureable lesion and/or progressed
lesion have to be confirmed by central image review of baseline and progression scan).
- ECOG performance status of 0 or 1.
- Liver function status of Child-Pugh Class A.
- Adequate bone morrow, liver, and renal function
- Patient has within normal range cardiac function confirmed by the enrolling clinical
institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
- Patients who are therapeutically anti-coagulated with an agent such as warfarin or
heparin are allowed to participate provided that no prior evidence of underlying
abnormality in these parameters exists. Close monitoring of at least weekly
evaluations will be performed until International normalized ratio (INR) is stable
(within Child Pugh class A threshold) based on a measurement at pre-dose, as defined
by the local standard of care.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any Cancer curatively treated < 3 years prior to study entry, except cervical
carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors
[Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades
lamina propria (T1)].
- Patients who are eligible for surgery, liver transplantation, ablation or
transarterial chemoembolization for HCC.
History of cardiac disease:
- Congestive heart failure New York Heart Association (NYHA) > class 2.
- Unstable angina (angina symptoms at rest, new-onset angina i.e. within the last 3
months) or myocardial infarction (MI) within the past 6 months prior to start of
screening.
- Cardiac arrhythmias requiring anti-arrhythmic therapy.
- QTc (corrected QT interval) > 480 ms
- Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic blood
pressure >90 mmHg despite optimal medical management).
- Ongoing infection > Grade 2 according to National Cancer Institute - Common Toxicity
Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is
allowed if no active replication (defined as abnormal Alanine aminotransferase [ALT]
>2x Upper limit normal [ULN] associated with Hepatitis B virus [HBV] DNA >20,000
IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
- Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR
at Screening to confirm the absence of central nervous system [CNS] disease if patient
had symptoms suggestive or consistent with CNS disease).
- History of interstitial lung disease (ILD).
- History of hepatic encephalopathy.
- History of organ allograft, cornea transplantation will be allowed.
- History or current evidence of retinal vein occlusion (RVO) or central serous
retinopathy (CSR).
- Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk
factor for RVO or CSR.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/09/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/02/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
14
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Kentucky
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Wien
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Bruxelles - Brussel
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Edegem
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Leuven
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Liege
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Guangdong
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Beijing
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Shanghai
Query!
Country [10]
0
0
Czechia
Query!
State/province [10]
0
0
Hradec Kralove
Query!
Country [11]
0
0
Czechia
Query!
State/province [11]
0
0
Olomouc
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Bordeaux
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Caen Cedex
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Lyon
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Marseille
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Nice Cedex 3
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Paris
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Saint-priest-en-jarez
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Vandoeuvre-les-nancy
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Baden-Württemberg
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Hessen
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Nordrhein-Westfalen
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Sachsen-Anhalt
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Berlin
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Hamburg
Query!
Country [26]
0
0
Hong Kong
Query!
State/province [26]
0
0
Hong Kong
Query!
Country [27]
0
0
Hungary
Query!
State/province [27]
0
0
Budapest
Query!
Country [28]
0
0
Hungary
Query!
State/province [28]
0
0
Debrecen
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Pecs
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Zalaegerszeg
Query!
Country [31]
0
0
Israel
Query!
State/province [31]
0
0
Haifa
Query!
Country [32]
0
0
Israel
Query!
State/province [32]
0
0
Jerusalem
Query!
Country [33]
0
0
Israel
Query!
State/province [33]
0
0
Petach Tikva
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Tel Aviv
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Emilia-Romagna
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Lazio
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Lombardia
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Aichi
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Chiba
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Fukuoka
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Kanagawa
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Osaka
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Saitama
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Tokyo
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Kyoto
Query!
Country [46]
0
0
Korea, Republic of
Query!
State/province [46]
0
0
Seoul Teugbyeolsi
Query!
Country [47]
0
0
Korea, Republic of
Query!
State/province [47]
0
0
Daegu
Query!
Country [48]
0
0
Korea, Republic of
Query!
State/province [48]
0
0
Seoul
Query!
Country [49]
0
0
New Zealand
Query!
State/province [49]
0
0
Auckland
Query!
Country [50]
0
0
Singapore
Query!
State/province [50]
0
0
Singapore
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
A Coruña
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Asturias
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Barcelona
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Pontevedra
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Madrid
Query!
Country [56]
0
0
Switzerland
Query!
State/province [56]
0
0
Bern
Query!
Country [57]
0
0
Taiwan
Query!
State/province [57]
0
0
Tainan
Query!
Country [58]
0
0
Taiwan
Query!
State/province [58]
0
0
Taipei
Query!
Country [59]
0
0
Thailand
Query!
State/province [59]
0
0
Chiang Mai
Query!
Country [60]
0
0
Thailand
Query!
State/province [60]
0
0
Khon Kaen
Query!
Country [61]
0
0
Thailand
Query!
State/province [61]
0
0
Songkhla
Query!
Country [62]
0
0
Turkey
Query!
State/province [62]
0
0
Istanbul
Query!
Country [63]
0
0
Turkey
Query!
State/province [63]
0
0
Mersin
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Birmingham
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study to investigate the potential clinical benefit of refametinib when given in
combination with sorafenib as first line treatment in patients with unresectable or
metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages.
Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to
receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15
patients at Stage 1 show at least partial response according to an objective criteria to
evaluate tumor size based on contrast enhancement [modified response evaluation criteria in
solid tumors (mRECIST)] assessed by external independent radiologists.
Refametenib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor
targets certain key proteins that are essential for the survival of the cancer cell. By
specifically targeting these proteins, refametinib in combination with sorafenib may stop
cancer growth. The growth of the tumor may be decreased by preventing these specific proteins
from functioning.
The primary endpoint (the most meaningful result to be tracked) of this study is based on the
rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with
refametinib in combination with sorafenib improves the response rate in this patient
population compared to historical results observed with the sorafenib only.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01915602
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01915602
Download to PDF